Ask AI

ClinicalThought

Share

Program Content

Activities

  • Adjuvant CDK4/6 Inhibitors for HR+/HER2- EBC
    Maximizing Patient Benefit With Adjuvant CDK4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 27, 2026

    Expires: August 26, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients.

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner